Enliven Therapeutics (NASDAQ:ELVN) CFO Benjamin Hohl Sells 6,018 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction on Monday, August 17th. The shares were sold at an average price of $58.58, for a total value of $352,534.44. Following the completion of the sale, the chief financial officer owned 40,036 shares in the company, valued at $2,345,308.88. This represents a 13.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl also recently made the following trade(s):

• On Friday, July 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The shares were sold at an average price of $52.64, for a total value of $316,787.52.
• On Wednesday, June 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The stock was sold at an average price of $43.80, for a total value of $263,588.40.

Enliven Therapeutics Trading Down 1.1%

Shares of NASDAQ:ELVN opened at $59.39 on Thursday. The business has a 50-day moving average price of $52.34 and a 200 day moving average price of $41.61. The company has a market capitalization of $4.35 billion, a price-to-earnings ratio of -35.56 and a beta of 0.27. Enliven Therapeutics, Inc. has a 12-month low of $14.78 and a 12-month high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, equities research analysts predict that Enliven Therapeutics, Inc. will post -1.67 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ELVN has been the topic of several recent analyst reports. The Goldman Sachs Group upped their price objective on shares of Enliven Therapeutics from $67.00 to $80.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Guggenheim dropped their target price on shares of Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a report on Thursday, August 6th. William Blair initiated coverage on shares of Enliven Therapeutics in a report on Tuesday. They issued an “outperform” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Friday, July 17th. Finally, Wall Street Zen cut Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $75.00.

Hedge Funds Weigh In On Enliven Therapeutics

Several institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its stake in shares of Enliven Therapeutics by 70.9% in the first quarter. Dimensional Fund Advisors LP now owns 681,715 shares of the company’s stock valued at $26,714,000 after purchasing an additional 282,822 shares during the period. Avidity Partners Management LP grew its holdings in shares of Enliven Therapeutics by 185.1% in the first quarter. Avidity Partners Management LP now owns 400,000 shares of the company’s stock valued at $15,680,000 after purchasing an additional 259,700 shares in the last quarter. Stempoint Capital LP purchased a new stake in Enliven Therapeutics during the 1st quarter worth approximately $14,247,000. Tema ETFs LLC increased its stake in Enliven Therapeutics by 41.0% during the 2nd quarter. Tema ETFs LLC now owns 60,694 shares of the company’s stock worth $3,080,000 after buying an additional 17,638 shares during the period. Finally, First Light Asset Management LLC acquired a new stake in Enliven Therapeutics during the 1st quarter worth approximately $7,913,000. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.